Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $3.7552W HIGH $9.40
Volume
10.30 K
Value Traded
254.24 K
Short % Float
1.14%
+7.54%Week
+7.67%1 Month
+29.11%3 Month
+58.52%6 Month
-92.08%5 Year
-91.4%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
38.97 M
EPS (TTM)
-2.29
P/E Ratio
-
Ent. Value
69.15 M
Total Shares
4.55 M
Float Shares
4.23 M
Insiders
7.15%
Institutions
42.06%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
HBIO Catalyst Timeline
Dated clinical, regulatory and corporate events for Harvard Bioscience, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Harvard Bioscience, Inc.
244Total events
1Upcoming
24Tier-1 (high impact)
2008 to 2027Coverage
Event history 50
▲Debt Royalty FinancingCorporate
Debt refinancing extended maturity to 2029, reduced annual debt service generating $3M annual cash savings, BroadOak $7.5M investment in convertible notes
◆Oral PresentationPresentation
Participation in KeyBanc Virtual Healthcare Forum fireside chat
▼Reverse Stock SplitCorporate
1-for-10 reverse stock split approved by board and stockholders
◆Pipeline PrioritizationCorporate
Announced focus on Translational Science products in February 2026
▲Debt Royalty FinancingCorporate
Debt refinancing with $40M credit facility from BroadOak Capital Partners
◆Management ChangeCorporate
BroadOak partner Bill Snider appointed to Board effective December 2025
▲Partnership / LicenseCorporate
Expanded distribution agreement with Fisher Scientific to include United States
▲Debt Royalty FinancingCorporate
Credit agreement amendment signed, extending refinance deadline
◆Management ChangeCorporate
John Duke to assume President & CEO role following Jim Green's retirement
●Quarterly UpdateCorporate
Q2 2025 revenue expected to be $20.4 million; gross margin guidance reiterated
◆Management ChangeCorporate
Rob Gagnon and Seth Benson appointed to Board effective July 2025
▲Quarterly UpdateCorporate
Cost reduction actions completed, expected savings of ~$1M per quarter starting Q2 2025
◆Poster PresentationPresentation
Poster presentation on VivaMARS Activity Monitoring System at SOT
▲Platform ValidationPreclinical
NIH adopts Mesh MEA technology for advanced neuro organoid research
●Manufacturing MilestoneCMC / Inspection
Full production of Mesh MEA expected in first half of 2025
◆Poster PresentationPresentation
Poster presentation at SPS Annual Meeting with initial VivaMARS results
◆Oral PresentationPresentation
Benchmark Healthcare House Call Virtual Conference fireside chat
Past FDA Catalysts and PDUFA Decisions
How HBIO actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Harvard Bioscience, Inc. is a diagnostics company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every HBIO program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Duke John DDirector, Officer (Chief Executive Officer) | Grant/Award | 75,000 180,000 held | $0.00 | 03/20/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in HBIO
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| TRI LOCUM PARTNERS LP | 0 % | 28.00 K | 10.03 K |
HBIO Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How HBIO ranks across every disease it competes in
Competitive Position is a premium feature
See how HBIO ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialHBIO News
-HBIO
Oct 6, 2026▲ +3.1%today
Harvard Bioscience Announces Creation of Scientific Advisory Board
Harvard Bioscience has established a Scientific Advisory Board to enhance its research and development efforts. The board, which will convene quarterly, includes five members, including CEO John Duke and four industry experts. This initiative is expected to guide the company's product roadmap and maximize value for stakeholders.
Read more →-HBIO
Jul 28, 2026Harvard Bioscience Schedules Second Quarter 2026 Earnings Conference Call for August 11, 2026 at 8:00 AM ET
Harvard Bioscience, Inc. will release its financial results for Q2 2026 on August 11, 2026. A conference call is scheduled for 8:00 AM ET to discuss these results. Analysts can register to ask questions, and financial information will be available on the company's investor website.
Read more →-HBIO
May 12, 2026▼ -20.9%on this news
Harvard Bioscience Announces First Quarter 2026 Financial Results
Harvard Bioscience, Inc. announced its financial results for Q1 2026, reporting revenues of $20.8 million with a gross margin of 59%. The company's net loss improved significantly from the prior year, reflecting a continued focus on operational efficiency. Progress in the consolidation of manufacturing operations is expected to enhance profitability. The company reaffirmed its full-year financial guidance, anticipating sales growth in its higher-margin NPI product pipeline in the second half of the year.
Read more →-HBIO
May 12, 2026▼ -20.9%on this news
NASDAQ: HBIO Harvard Bioscience Investor Overview May 2026
Harvard Bioscience (HBIO) has provided an investor overview outlining its strategic direction and financial performance expectations for May 2026. The company anticipates a revenue growth of 2-4% for FY26, along with a consistent adjusted gross margin. Recent actions include new executive appointments and a refinancing of debt, which is expected to enhance financial flexibility. The focus has shifted towards translational science products, with ongoing manufacturing consolidation aimed at boosting operational efficiencies.
Read more →-HBIO
May 11, 2026Harvard University Expands Multifaceted Research Alliance with Northpond Labs to Advance Solutions in Healthcare
Harvard University has expanded its research alliance with Northpond Labs to promote healthcare solutions through additional funding. This collaboration builds on a previous successful partnership established in 2020, which led to significant projects like EnPlusOne Biosciences. The new funding will primarily benefit the Lab for Bioengineering Research and Innovation and support direct research at Harvard Medical School. Both institutions expressed optimism about translating academic research into impactful healthcare innovations that will ultimately benefit patients worldwide.
Read more →-HBIO
May 7, 2026▼ -6.2%on this news· ran to -25% by day 3shared move
Harvard Bioscience to Participate in Upcoming Investor Conferences
Harvard Bioscience, Inc. announced that CEO John Duke and CFO Mark Frost will participate in upcoming investor conferences, including the Sidoti Micro Cap Conference and a virtual Benchmark Healthcare Conference. The Sidoti event features a fireside chat presentation scheduled for May 21, 2026. Interested investors can access a live webcast of the fireside chat and an archived replay on the company's Investor Relations website. This moves signals the company's proactive approach in engaging with the investment community.
Read more →-HBIO
Apr 28, 2026▼ -5.6%on this news
Harvard Bioscience Schedules First Quarter 2026 Earnings Conference Call for May 12, 2026 at 8:00 AM ET
Harvard Bioscience, Inc. will release its financial results for Q1 2026 on May 12, 2026, before market opening. A conference call will follow at 8:00 AM ET, allowing analysts to inquire about the results. The earnings release and presentation will be accessible on the company's investor relations website.
Read more →-HBIO
Mar 17, 2026NASDAQ: HBIO Harvard Bioscience Investor Overview March 202 6
Harvard Bioscience (HBIO) has provided an investor overview highlighting its growth prospects and financial performance for FY25, projecting $87 million in revenue and 58% adjusted gross margin. The company is refocusing its strategy on Translational Science tools and has made significant leadership changes. Recent actions include debt refinancing that enhances financial flexibility and a strategic consolidation of operations to improve margins. With a strong customer base and ongoing innovation, HBIO aims to navigate the challenges presented by regulatory and market shifts.
Read more →-HBIO
Mar 12, 2026Harvard Bioscience Announces Fourth Quarter and Full-Year 2025 Financial Results
Harvard Bioscience reported its fourth quarter and full-year financial results for 2025, revealing revenues of $23.7 million in Q4 and $86.6 million for the year. The company experienced a net loss of $56.7 million, attributed to goodwill impairment and other costs. Looking ahead, Harvard Bioscience introduced guidance for 2026, anticipating revenue growth driven by new product innovations in translational science.
Read more →-HBIO
Mar 9, 2026▼ -11.6%on this newsshared move
Harvard Bioscience Announces Reverse Stock Split - March 6, 2026
Harvard Bioscience announced a 1-for-10 reverse stock split approved by shareholders to enhance its stock price and comply with Nasdaq listing requirements. The split will take effect on March 13, 2026, reducing outstanding shares from approximately 44.7 million to about 4.5 million. Shareholders will receive cash for any fractional shares resulting from the split.
Read more →-HBIO
Mar 6, 2026Harvard Bioscience Announces Reverse Stock Split
Harvard Bioscience has announced a 1-for-10 reverse stock split, set to take effect on March 13, 2026, following stockholder approval. This action is intended to increase the trading price of its common stock to meet the Nasdaq Capital Market's listing requirements. The number of shares will decrease from approximately 44.7 million to about 4.5 million, with fractional shares being compensated in cash. The stock split highlights the company's current challenges in maintaining its listing status.
Read more →-HBIO
Mar 3, 2026Harvard Bioscience to Participate in KeyBanc’s Virtual Healthcare Forum
Harvard Bioscience, Inc. announced its participation in KeyBanc Capital Markets' Virtual Healthcare Forum on March 17th. CEO John Duke and Interim CFO Mark Frost will engage in a fireside chat, which will be accessible via the company's investor relations website. This event aims to enhance communication with investors and stakeholders.
Read more →-HBIO
Feb 26, 2026Harvard Bioscience Schedules Fourth Quarter 2025 Earnings Conference Call for March 12, 2026 at 8:00 AM ET
Harvard Bioscience, Inc. will release its financial results for Q4 2025 on March 12, 2026, before the market opens. A conference call will follow at 8:00 AM ET, allowing participants to ask questions after registering. Financial details will be accessible on the company's investor relations website.
Read more →-HBIO
Feb 10, 2026▲ +13.4%on this news
Harvard Bioscience Announces Preliminary Fourth Quarter Financial Results, Positive Outlook for 2026 & Outlines Long-Term Strategic Focus Areas
Harvard Bioscience announced preliminary financial results for Q4 2025, showcasing a positive outlook for 2026. The company aims to transition from a traditional tools provider to a leader in Translational Science, focusing on sustainable growth through strategic pillars. CEO John Duke expressed confidence in revenue and EBITDA growth, with detailed results to be released on March 12, 2026.
Read more →-HBIO
Jan 30, 2026▼ -6.7%on this news
Harvard Bioscience Announces Strategic Consolidation of Manufacturing Operations to Improve Efficiency and Support Long-Term Growth
Harvard Bioscience announced a strategic consolidation of its manufacturing operations, closing its Holliston, MA facility and transitioning production to Minneapolis, MN, as well as relocating some operations to Europe. This move aims to enhance efficiency and achieve significant cost savings. The consolidation is expected to be completed by Q1 2027, with a comprehensive transition plan in place to ensure continuity.
Read more →-HBIO
Jan 12, 2026HBio Confidential 1 NASDAQ: HBIO HBIO Investor Overview January 202 6
HBio released an investor overview highlighting its forward-looking statements regarding financial performance and operational growth. Notably, the company's Q3 revenue reached $20.6 million, aligning with the high end of its guidance range, alongside an adjusted EBITDA increase. The firm is well-positioned in various markets, marking strong operational improvements and emphasizing an efficient management structure focused on sustainability and enhanced cash flow. The document also discusses ongoing product adoption and initiatives to strengthen its capital structure.
Read more →-HBIO
Dec 17, 2025▲ +12.4%on this news
Harvard Bioscience Announces the Successful Completion of Debt Refinancing with Comprehensive Growth Financing Package
Harvard Bioscience has successfully completed a $40 million debt refinancing agreement with BroadOak Capital Partners. This financing includes three term loans aimed at retiring existing debt and improving the company's financial stability. Additionally, Bill Snider from BroadOak has joined the board of directors, further strengthening the company's leadership as it focuses on growth and strategic priorities.
Read more →-HBIO
Nov 6, 2025▼ -7.3%on this news
Harvard Bioscience Announces Third Quarter 2025 Financial Results
Harvard Bioscience reported its third quarter 2025 financial results, showing a revenue of $20.6 million, a slight decrease from the previous year. However, the company noted improved customer engagement and a growing backlog, indicating positive momentum. Despite a net loss of $1.2 million, adjusted EBITDA rose to $2.0 million. The company anticipates continued growth in the fourth quarter.
Read more →-HBIO
Oct 30, 2025▲ +41.1%on this news
Harvard Bioscience Schedules Third Quarter 2025 Earnings Conference Call for November 6, 2025 at 8:00 AM ET
Harvard Bioscience, Inc. will announce its Q3 2025 financial results on November 6, 2025. The announcement will occur before market opening, followed by a conference call at 8:00 AM ET. Participants can register to ask questions, and financial details will be available on the company's investor relations website.
Read more →-HBIO
Sep 16, 2025▲ +10.3%on this news
Harvard Bioscience Expands Distribution Agreement with Fisher Scientific to Include United States
Harvard Bioscience has expanded its distribution agreement with Fisher Scientific to include the U.S. market, enhancing access to its products such as pumps and spectrophotometers. This collaboration aims to improve customer experience through streamlined ordering and localized support. The agreement also introduces advanced technologies for organoid research, furthering Harvard Bioscience's commitment to scientific discovery.
Read more →About Harvard Bioscience, Inc.
Headquarters84 OCTOBER HILL RD, HOLLISTON, MA, 01746
BIOPHARMAWATCH ELITE PLUS
Trade the next HBIO catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime